|
1
|
Choi JW, Herr DR, Noguchi K, et al: LPA
receptors, subtypes and biological actions. Annu Rev Pharmacol
Toxicol. 50:157–186. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chun J, Hla T, Lynch KR, Spiegel S and
Moolenaar WH: Inter-national Union of Basic and Clinical
Pharmacology. LXXVIII. Lysophospholipid Receptor Nomenclature.
Pharmacol Rev. 62:579–587. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
An S, Bleu T, Hallmark OG and Goetzl EJ:
Characterization of a novel subtype of human G protein-coupled
receptor for lysophosphatidic acid. J Biol Chem. 273:7906–7910.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lin ME, Herr DR and Chun J:
Lysophosphatidic acid LPA. receptors, signaling properties and
disease relevance. Prostaglandins Other Lipid Mediat. 91:130–138.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Eichholtz T, Jalink K, Fahrenfort I and
Moolenaar WH: The bioactive phospholipid lysophosphatidic acid is
released from activated platelets. Biochem J. 291:677–680.
1993.PubMed/NCBI
|
|
6
|
Stracke ML, Krutzsch HC, Unsworth EJ,
Arestad A, Cioce V, Schiffmann E and Liotta LA: Identification,
purification, and partial sequence analysis of autotaxin, a novel
motility-stimulating protein. J Biol Chem. 267:2524–2529.
1992.PubMed/NCBI
|
|
7
|
Umezu-Goto M, Kishi Y, Taira A, et al:
Autotaxin has lysophospholipase D activity leading to tumor cell
growth and motility by lysophosphatidic acid production. J Cell
Biol. 158:227–233. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mills GB and Moolenaar WH: The emerging
role of lysophosphatidic acid in cancer. Nat Rev Cancer. 3:582–591.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Schulte KM, Beyer A, Kohrer K, Oberhauser
S and Roher HD: Lysophosphatidic acid, a novel lipid growth factor
for human thyroid cells, over-expression of the high-affinity
receptor edg4 in differentiated thyroid cancer. Int J Cancer.
92:249–256. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Fang X, Schummer M, Mao M, et al:
Lysophosphatidic acid is a bioactive mediator in ovarian cancer.
Biochim Biophys Acta. 1582:257–264. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kitayama J, Shida D, Sako A, et al:
Over-expression of lysophosphatidic acid receptor-2 in human
invasive ductal carcinoma. Breast Cancer Res. 6:R640–R646. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Shida D, Watanabe T, Aoki J, et al:
Aberrant expression of lysophosphatidic acid LPA., receptors in
human colorectal cancer. Lab Invest. 84:1352–1362. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liu S, Umezu-Goto M, Murph M, et al:
Expression of autotaxin and lysophosphatidic acid receptors
increases mammary tumorigenesis, invasion, and metastases. Cancer
Cell. 15:539–550. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Boucharaba A, Serre C-M, Gres S, et al:
Platelet-derived lysophosphatidic acid supports the progression of
osteolytic bone metastases in breast cancer. J Clin Invest.
114:1714–1725. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
David M, Wannecq E, Descotes F, et al:
Cancer cell expression of autotaxin controls bone metastasis
formation in mouse through lysophosphatidic acid-dependent
activation of osteoclasts. PLoS One. 5:e97412010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Boucharaba A, Serre CM, Guglielmi J,
Bordet JC, Clezardin P and Peyruchaud O: The type 1
lysophosphatidic acid receptor is a target for therapy in bone
metastases. Proc Natl Acad Sci USA. 103:9643–9648. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ohta H, Sato K, Murata N, et al: Ki16425,
a subtype-selective antagonist for EDG-family lysophosphatidic acid
receptors. Mol Pharmacol. 64:994–1005. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lelekakis M, Moseley JM, Martin TJ, et al:
A novel orthotopic model of breast cancer metastasis to bone. Clin
Exp Metastasis. 17:163–170. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hama K, Aoki J, Fukaya M, et al:
Lysophosphatidic acid and autotaxin stimulate cell motility of
neoplastic and non-neoplastic cells through LPA1. J Biol Chem.
279:17634–17639. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Pradere JP, Klein J, Gres S, et al: LPA1
receptor activation promotes renal interstitial fibrosis. J Am Soc
Nephrol. 18:3110–3118. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Aslakson CJ and Miller FR: Selective
events in the metastatic process defined by analysis of the
sequential dissemination of subpopulations of a mouse mammary
tumor. Cancer Res. 52:1399–1405. 1992.PubMed/NCBI
|
|
22
|
Akhtari M, Mansuri J, Newman KA, Guise TM
and Seth P: Biology of breast cancer bone metastasis. Cancer Biol
Ther. 7:3–9. 2007. View Article : Google Scholar
|
|
23
|
Ferrara N and Kerbel RS: Angiogenesis as a
therapeutic target. Nature. 438:967–974. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Jeon ES, Lee IH, Heo SC, et al:
Mesenchymal stem cells stimulate angiogenesis in a murine xenograft
model of A549 human adenocarcinoma through an LPA1
receptor-dependent mechanism. Biochim Biophys Acta. 1801:1205–1213.
2010. View Article : Google Scholar
|
|
25
|
Donegan WL: Tumor-related prognostic
factors for breast cancer. CA Cancer J Clin. 47:28–51. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Eyles J, Puaux AL, Wang X, et al: Tumor
cells disseminate early, but immunosurveillance limits metastatic
outgrowth, in a mouse model of melanoma. J Clin Invest.
120:2030–2039. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Witt AE, Hines LM, Collins NL, et al:
Functional proteomics approach to investigate the biological
activities of cDNAs implicated in breast cancer. J Proteome Res.
5:599–610. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Taghavi P, Verhoeven E, Jacobs JJ, et al:
In vitro genetic screen identifies a cooperative role for LPA
signaling and c-Myc in cell transformation. Oncogene. 27:6806–6816.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Stopeck AT, Lipton A, Body JJ, et al:
Denosumab compared with zoledronic acid for the treatment of bone
metastases in patients with advanced breast cancer, A R andomized,
double-blind study. J Clin Oncol. 28:5132–5139. 2010. View Article : Google Scholar
|
|
30
|
Noguchi K, Herr D, Mutoh T and Chun J:
Lysophosphatidic acid LPA. and its receptors. Curr Opin Pharmacol.
9:15–23. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Boucharaba A, Guillet B, Menaa F, Hneino
M, van Wijnen AJ, Clezardin P and Peyruchaud O: Bioactive lipids
lysophosphatidic acid and sphingosine 1-phosphate mediate breast
cancer cell biological functions through distinct mechanisms. Oncol
Res. 18:173–184. 2009. View Article : Google Scholar
|
|
32
|
Li TT, Alemayehu M, Aziziyeh AI, et al:
Beta-arrestin/Ral signaling regulates lysophosphatidic
acid-mediated migration and invasion of human breast tumor cells.
Mol Cancer Res. 7:1064–1077. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Steeg PS, Bevilacqua G, Pozzatti R, Liotta
LA and Sobel ME: Altered expression of NM23, a gene associated with
low tumor metastatic potential, during adenovirus 2 Ela inhibition
of experimental metastasis. Cancer Res. 48:6550–6554.
1998.PubMed/NCBI
|
|
34
|
Steeg PS, Horak CE and Miller KD:
Clinical-translational approaches to the Nm23-H1 metastasis
suppressor. Clin Cancer Res. 14:5006–5012. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Horak CE, Lee JH, Elkahloun AG, et al:
Nm23-H1 suppresses tumor cell motility by down-regulating the
lysophosphatidic acid receptor EDG2. Cancer Res. 67:7238–7246.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Horak CE, Mendoza A, Vega-Valle E, et al:
Nm23-H1 suppresses metastasis by inhibiting expression of the
lysophosphatidic acid receptor EDG2. Cancer Res. 67:11751–11759.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Berthier A, Seguin S, Sasco AJ, et al:
High expression of gabarapl1 is associated with a better outcome
for patients with lymph node-positive breast cancer. Br J Cancer.
102:1024–1031. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Boissier S, Ferreras M, Peyruchaud O, et
al: Bisphosphonates inhibit breast and prostate carcinoma cell
invasion, an early event in the formation of bone metastases.
Cancer Res. 60:2949–2954. 2000.PubMed/NCBI
|
